NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma

•STK33 is associated with the development of DLBCL and drug resistance.•Ectopic expression of STK33 promotes resistance of DLBCL cells to cisplatin.•Silencing of STK33 inhibits the growth of DLBCL cells and resistance to cisplatin.•STK33 activates the Hedgehog signaling pathway.•STK33 is regulated by the transcription factor NFYB.